Liposomes are small, artificial and lipid-based bilayered spherical vesicles, which are created spontaneously by hydrated phospholipids. Owing to their ability to encapsulate bioactive hydrophilic, amphipathic, and lipophilic molecules, liposomes are extensively used as efficient delivery systems for antigens or drugs.

The global liposome manufacturing market size is estimated to reach USD 2.34 billion by 2035, growing at a CAGR of 9.7% during the forecast period.

Over the years, several companies involved in the development of liposomes have made significant efforts in conducting clinical trials for evaluating the efficacy of liposome-based therapeutics, for the treatment of various oncological disorders. The number of such studies and their geographical distribution are important indicators of therapeutic viability (reflecting the current interest of industry stakeholders) and future potential (which markets the product is likely to be available soon after approval) of the novel and innovative pharmacological interventions.

This domain has witnessed a gradual increase in clinical research activity over the past few years. This growth can be attributed to the initiatives undertaken by several industry and non-industry players that are actively evaluating the efficacy of liposome-based therapeutics for a wide range of indications. In 2020, 12 trials were initiated / planned worldwide. It is worth mentioning that, in 2022 (till October), 55 new trials in this domain have been registered / initiated worldwide.

Further, the most targeted disease area within oncological disorders is ovarian cancer, with 226 trials registered in the given time period. Other popular indications for which multiple trials have been registered, include breast cancer (120), fallopian tube cancer (103), peritoneal cancer (88) and acute myeloid leukemia (82).

The research activity related to liposomes is growing at a substantial pace in order to investigate their potential across various therapeutic applications, including disease diagnostics and targeted drug delivery. As a result, there has been a significant increase in the number of scientific articles published in this domain.

There has been a continuous increase in the number of articles published in this domain, during the given time period. This can be attributed to the extensive research being carried out to investigate the global status, trends, and therapeutic potential of liposomes. It is worth highlighting that in 2021, 1,208 articles related to liposomes were published. This number is expected to rise in 2022, as till July, more than 800 articles have already been published.

Further, majority of the articles (51%) are focused on evaluating liposomes for use in cancer therapy. This can be attributed to the fact that liposomes can actively target tumor tissues when used in combination with antibodies. This is followed by articles focused on the applications of liposomes in drug delivery (24%), and protein and peptide delivery (9%), which is indicative of the extensive research activities and clinical trials being conducted to evaluate the therapeutic potential of liposomes.

The maximum number of articles (244) were published in the International Journal of Pharmaceutics during the given time period. This is followed by articles published under other prominent journals, namely Pharmaceutics (214), Journal of Controlled Release (175), and International Journal of Nanomedicine (167).

Research Methodology

Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Liposome Manufacturing Market.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. 

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/liposome-manufacturing-market.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:

Roots Analysis

+1 (415) 800 3415

[email protected]